Related Experiment Video
Updated: Aug 6, 2026
08:08
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
The serotonin pathway in pulmonary hypertension
1INSERM U651, Département de Physiologie, Hôpital Henri-Mondor, Créteil.
Archives Des Maladies Du Coeur Et Des Vaisseaux
|August 2, 2006
Summary
Pulmonary artery smooth muscle cell proliferation in pulmonary hypertension is linked to serotonin transporter (5-HTT) overexpression. Inhibiting 5-HTT may offer a new treatment strategy for this condition.
Area of Science:
- Cardiovascular Research
- Pulmonary Medicine
- Molecular Biology
Background:
- Pulmonary artery hypertension (PH) involves abnormal pulmonary artery smooth muscle cell (PA-SMC) proliferation.
- The exact cause of PA-SMC proliferation in PH is unclear, with possibilities including inherent cell characteristics or external factors like growth factors.
- Previous research indicated that PA-SMCs from idiopathic PH (iPH) patients exhibit an exaggerated proliferative response to serotonin.
Purpose of the Study:
- To investigate the role of the serotonin transporter (5-HTT) in the abnormal proliferation of PA-SMCs in pulmonary hypertension.
- To explore the potential of targeting 5-HTT as a therapeutic strategy for PH.
Main Methods:
- Examined cultured PA-SMCs from iPH patients for their proliferative response to serotonin and serum.
- Investigated the mechanism of serotonin-mediated mitogenesis, focusing on 5-HTT.
- Reviewed experimental studies using transgenic animals with altered 5-HTT expression and gene-disrupted mice.
- Analyzed the association between 5-HTT gene polymorphism and PH severity in patients with chronic lung disease.
Main Results:
- Cultured PA-SMCs from iPH patients demonstrated an excessive proliferative response to serotonin.
- Overexpression of the serotonin transporter (5-HTT) was identified as the cause of this abnormal response.
- Experimental models showed that increased 5-HTT in smooth muscle leads to pulmonary vascular remodeling and PH.
- Genetic disruption of 5-HTT protected mice against PH, and 5-HTT inhibitors reversed experimental PH.
- A correlation was observed between a specific 5-HTT gene polymorphism and PH severity in patients with chronic lung disease.
Conclusions:
- Overexpression of the serotonin transporter (5-HTT) is a key factor in the excessive proliferation of PA-SMCs and the development of pulmonary hypertension.
- Selective inhibition of 5-HTT-mediated PA-SMC proliferation presents a promising avenue for novel PH treatments.
More Related Videos
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.